Craneware (LON:CRW) Given “Buy” Rating at Shore Capital

Craneware (LON:CRW)‘s stock had its “buy” rating reissued by research analysts at Shore Capital in a research note issued to investors on Tuesday,Digital Look reports. They presently have a GBX 2,850 price objective on the stock. Shore Capital’s price target suggests a potential upside of 61.02% from the stock’s previous close.

Separately, Berenberg Bank restated a “buy” rating and set a GBX 2,900 price target on shares of Craneware in a report on Tuesday. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of GBX 2,873.67.

Craneware Price Performance

Shares of LON CRW opened at GBX 1,770 on Tuesday. The firm’s 50-day simple moving average is GBX 1,994.81 and its 200 day simple moving average is GBX 2,188. Craneware has a fifty-two week low of GBX 1,330 and a fifty-two week high of GBX 2,644. The stock has a market cap of £628.51 million, a P/E ratio of 32.07 and a beta of 0.28. The company has a quick ratio of 1.00, a current ratio of 0.63 and a debt-to-equity ratio of 12.22.

Craneware Company Profile

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in healthcare financial and operational transformation, delivering cutting-edge technologies that drive measurable impact. Our Trisus® cloud ecosystem unifies data, revenue intelligence, margin intelligence, and advanced analytics, enabling healthcare organizations to optimize performance, improve financial sustainability, and drive strategic growth. As a trusted Microsoft partner, we provide future-ready solutions-including the Best in KLAS Trisus Chargemaster – that simplify the complexities of healthcare finance and operations.